(Q40485738)

20 September 2017

1 reference

title

Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential (English)

1 reference

20 September 2017

1 reference

L R Wiseman

1

1 reference

20 September 2017

P Benfield

series ordinal

2

1 reference

20 September 2017

language of work or name

1 reference

1 February 1993

1 reference

20 September 2017

1 reference

20 September 2017

volume

45

1 reference

20 September 2017

issue

2

1 reference

20 September 2017

page(s)

295-317

1 reference

BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.

20 September 2017

cites work

1 reference

12 December 2020

Alternative antimicrobial agents to contemporary treatment of infections cawed by Corynebactaimm parvam ( Propiomibacierimm acmes)

1 reference

12 December 2020

Phase I study of multiple-dose cefprozil and comparison with cefaclor

1 reference

12 December 2020

In vitro activity of BMY 28100, a new oral cephalosporin

1 reference

12 December 2020

Cefprozil versus cefaclor in the treatment of acute and uncomplicated urinary tract infections. Cefprozil Multicenter Study Group

1 reference

12 December 2020

Pharmacology and Pharmacokinetics of Cefprozil

1 reference

12 December 2020

Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.

1 reference

12 December 2020

Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil

1 reference

12 December 2020

In vitro activity and beta-lactamase stability of the oral cephalosporin BMY-28100

1 reference

12 December 2020

Comparative efficacy and safety of cefprozil (BMY-28100) and cefaclor in the treatment of acute group A beta-hemolytic streptococcal pharyngitis

1 reference

12 December 2020

Phase I study of single-dose BMY-28100, a new oral cephalosporin

1 reference

12 December 2020

Comparison of cefprozil and cefaclor for treatment of acute urinary tract infections in women

1 reference

12 December 2020

Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration

1 reference

12 December 2020

Penetration of cefprozil into tonsillar and adenoidal tissues

1 reference

12 December 2020

A comparison of cephalosporins and penicillins in the treatment of group A beta-hemolytic streptococcal pharyngitis: a meta-analysis supporting the concept of microbial copathogenicity

1 reference

12 December 2020

Excretion of cefprozil into human breast milk

1 reference

12 December 2020

Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor

1 reference

12 December 2020

Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans

1 reference

12 December 2020

Cefprozil versus cefaclor in the treatment of mild to moderate skin and skin-structure infections. The Cefprozil Multicenter Study Group

1 reference

12 December 2020

Comparative efficacy and safety of cefprozil and cefaclor in the treatment of acute uncomplicated urinary tract infections

1 reference

12 December 2020

Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany

1 reference

12 December 2020

A noncomparative study of cefprozil at two dose levels in the treatment of acute uncomplicated bacterial sinusitis

1 reference

12 December 2020

Pharmacokinetics of cefprozil in infants and children

1 reference

12 December 2020

In vitro activity of cefprozil (BMY 28100) and cefepime (BMY 28142) against Streptococcus pneumoniae, Branhamella catarrhalis, and Haemophilus influenzae, and provisional interpretive criteria for disk diffusion and dilution susceptibility tests wit

1 reference

12 December 2020

Comparative in vitro activity of the new oral cephalosporin BMY-28100.

1 reference

12 December 2020

Pharmacokinetics and tissue penetration of cefprozil

1 reference

12 December 2020

Safety Profile of Cefprozil

1 reference

12 December 2020

In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporin

1 reference

12 December 2020

Comparative trial of cefprozil vs. amoxicillin clavulanate potassium in the treatment of children with acute otitis media with effusion.

1 reference

12 December 2020

Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers

1 reference

12 December 2020

Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment

1 reference

12 December 2020

In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to six new oral cephalosporins

1 reference

12 December 2020

Comparative antibacterial activity of the new oral cephalosporin BMY-28100

1 reference

12 December 2020

In-vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid

1 reference

12 December 2020

In vitro activity of BMY-28100, a new oral cephalosporin

1 reference

12 December 2020

Effect of antacid on the bioavailability of cefprozil

1 reference

12 December 2020

Simultaneous high-performance liquid chromatographic analysis of cefprozil diastereomers in a pharmacokinetic study

1 reference

12 December 2020

BMY 28100, a new oral cephalosporin

1 reference

12 December 2020

In vitro activity of BMY-28100 against common isolates from pediatric infections

1 reference

12 December 2020

Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin

1 reference

12 December 2020

10.2165/00003495-199345020-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

20 September 2017

1000705720

0 references

1 reference